跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NUVAXOVID DISPERSION INYECTABLE - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
NUVAXOVID DISPERSION INYECTABLE
Approved
STANDARD
NUVAXOVID DISPERSION INYECTABLE
Novavax Cz A.S.
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Feb 3, 2022
Approval ID
4e9a36bf95c9712e
Company
Novavax Cz A.S.
Type
Standard
Approval Details
Approval Id
4e9a36bf95c9712e
Drug Cima Aemps Name
NUVAXOVID DISPERSION INYECTABLE
Register Number
1211618001
Holder Company Name
Novavax Cz A.S.
Marketing Company Name
Sanofi Aventis S.A.
Holder Company Detail Path
/organization/novavax-cz-a-s
Authorization Date
2022-02-03
Dosage Form
DISPERSIÓN INYECTABLE
Dose
0,5 ml
Route Of Administration
VÍA INTRAMUSCULAR
Prescription Type
Medicamento Sujeto A Prescripción Médica
Commercialized
No
Company Name
Novavax Cz A.S.
Company Detail Path
/organization/novavax-cz-a-s
Company Information
Pharmaceutical Company Name
NOVAVAX CZ a.s.
Country Name
Czech Republic
City Name
praha,hlavní město praha,country_cz
Address
Líbalova 2348/1
Active Ingredients
VACUNA DE PROTEINA RECOMBINANTE DE LA ESPICULA FRENTE A COVID-19 (NOVAVAX)
5 µg/pulsación
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Feb 3, 2022
Approval ID
4e9a36bf95c9712e
Type
Standard
Back to CIMA-AEMPS Approvals